Psoriatic arthritis (PsA) is a large volume of our clinical practice and its management can be challenging. Traditional DMARDs have been used over last six decades and observational studies have substantiated an effective use of many of these drugs. However, in last two decades use of anti-TNF agents has brought a new dimension in treatment of PsA and may other autoimmune diseases. Regulatory role of the Th17 cells and its cytokines in the pathogenesis of PsA has successfully paved the foundations of anti-IL antibody based therapies in PsA. Newer therapies targeting the IL-23/IL-17 cytokines and its signaling proteins are now in development and bringing new promises for management of PsA. Herein, we provide an overview of the landscape of drug therapies, including IL-17, IL-12/23, IL-23 inhibitors, and janus kinase (JAK) inhibitors, as well as those in development, such as RORγt inhibitors, anti-NGF agents, mTOR inhibitors and T cell ion-channel blockers.

银屑病关节炎（PsA）在我们的临床实践中占很大比重，其管理可能具有挑战性。在过去的六十年中，传统的DMARD已被使用，观察研究证实了其中许多药物的有效使用。然而，在最近的二十年中，抗TNF药物的使用为PsA和其他自身免疫性疾病的治疗带来了新的局面。Th17细胞及其细胞因子在PsA发病机理中的调控作用已成功为PsA中基于抗IL抗体的疗法奠定了基础。针对IL-23 / IL-17细胞因子及其信号蛋白的新疗法正在开发中，并为PsA的管理带来了新的希望。在此，我们概述了药物治疗的前景，包括IL-17，IL-12 / 23，IL-23抑制剂和janus激酶（JAK）抑制剂，